Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA-101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyelonephritis

Next Previous
Search
Trial Profile

A Multicenter, Double-Blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA-101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyelonephritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceftolozane (Primary) ; Ceftazidime
  • Indications Bacterial infections; Pyelonephritis; Urinary tract infections
  • Focus Therapeutic Use
  • Acronyms CXA-101-03
  • Sponsors Calixa Therapeutics; Cubist Pharmaceuticals

Most Recent Events

  • 21 Apr 2012 Additional trial locations (Czech Republic, Belgium) identified as reported by EudraCT.
  • 12 Sep 2010 Results presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
  • 30 Jun 2010 All study objectives have been met, according to a Cubist Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top